Skip to main content
. 2017 Apr 13;16:78. doi: 10.1186/s12943-017-0639-2

Fig. 1.

Fig. 1

The level of DC-SIGNR in gastric cancer patients and its clinical significance. a, the level of DC-SIGNR in gastric cancer patients serum (n = 207) compared with healthy group (n = 197). DC-SIGNR level was examined by ELISA. b, examination of the correlation between DC-SIGNR level and advanced pathological stage. c, DC-SIGNR in healthy group (n = 197); patients with no metastasis (n = 151), liver metastasis (n = 43), or lung, ovary and colon metastasis (n = 17)